Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.
Open Patient data Explorative Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Thyroid. 2020 May;30(5):672-680. doi: 10.1089/thy.2019.0672. Epub 2020 Mar 3.
Dementia is an increasing burden to the health care system. It is currently debated whether hyperthyroidism is associated with a risk of dementia. Our aim was to determine the risk of dementia in hyperthyroid individuals and whether this was associated with duration of hyperthyroidism. Risk of dementia in hyperthyroid individuals was evaluated in two cohorts and matched reference populations. The Danish National Patient Registry (DNPR) cohort is a registry-based Danish nationwide cohort followed for a median of 7.2 years (from 1995 to 2013), whereas the OPENTHYRO registry cohort comprises 235,547 individuals who had at least one serum thyrotropin (TSH) measurement in the period from 1995 to 2011 and was followed for a median of 7.3 years. Each hyperthyroid case was matched with four controls according to age and sex using density sampling. Hyperthyroidism was defined as either an International Classification of Diseases Version 10 (ICD-10) diagnosis of toxic nodular goiter (TNG) or Graves' disease (GD), or two measurements of a TSH below 0.3 mU/L in the DNPR and OPENTHYRO registry cohort, respectively. The primary outcome was all-cause dementia, defined as either an ICD-10 code of dementia or prescription of medicine for dementia, with subgroup analyses of vascular dementia and Alzheimer's disease. The DNPR cohort had 56,128 patients with hyperthyroidism, 2689 of whom were registered with dementia. The reference population had 224,512 individuals, of whom 10,199 had dementia (hazard ratio 1.17; 95% confidence interval [CI]: 1.12-1.23). Risk of dementia, whether Alzheimer's or vascular, was higher in both GD and TNG. The OPENTHYRO registry cohort constituted 2688 hyperthyroid individuals and 10,752 euthyroid control individuals of whom 190 and 473 individuals, respectively, were subsequently diagnosed with dementia (HR 1.06; 95% CI: 0.89-1.26). For each 6 months of decreased TSH, the risk of all-cause dementia was significantly higher (HR 1.16; 95% CI: 1.12-1.22). Using large-scale registry-based data, we found increased risk of dementia in hyperthyroid individuals. Every 6 months of decreased TSH was associated with increased risk of dementia by 16%, compared with individuals with normal TSH. Our data support early diagnosis and intervention in patients with hyperthyroidism.
痴呆症给医疗保健系统带来了越来越大的负担。目前人们正在争论甲状腺功能亢进是否与痴呆症的风险有关。我们的目的是确定甲状腺功能亢进个体患痴呆症的风险,以及这种风险是否与甲状腺功能亢进的持续时间有关。
在两个队列和匹配的参考人群中评估了甲状腺功能亢进个体患痴呆症的风险。丹麦国家患者登记处 (DNPR) 队列是一个基于登记的丹麦全国性队列,中位随访时间为 7.2 年(1995 年至 2013 年),而 OPENTHYRO 登记处队列包含 235547 名个体,他们在 1995 年至 2011 年期间至少有一次血清促甲状腺激素 (TSH) 测量,并中位随访 7.3 年。每个甲状腺功能亢进病例都根据年龄和性别使用密度抽样与四个对照匹配。甲状腺功能亢进症的定义为国际疾病分类第 10 版 (ICD-10) 诊断的毒性结节性甲状腺肿 (TNG) 或格雷夫斯病 (GD),或在 DNPR 和 OPENTHYRO 登记处队列中两次 TSH 测量值均低于 0.3 mU/L。主要结局是所有原因导致的痴呆症,定义为 ICD-10 痴呆症代码或痴呆症药物处方,对血管性痴呆症和阿尔茨海默病进行亚组分析。
DNPR 队列中有 56128 名甲状腺功能亢进患者,其中 2689 名患有痴呆症。参考人群有 224512 人,其中 10199 人患有痴呆症(危险比 1.17;95%置信区间 [CI]:1.12-1.23)。GD 和 TNG 患者的痴呆症风险(无论是阿尔茨海默病还是血管性痴呆症)均较高。OPENTHYRO 登记处队列包括 2688 名甲状腺功能亢进患者和 10752 名甲状腺功能正常的对照个体,其中分别有 190 名和 473 名患者随后被诊断为痴呆症(HR 1.06;95%CI:0.89-1.26)。TSH 每降低 6 个月,全因痴呆症的风险显著增加(HR 1.16;95%CI:1.12-1.22)。
使用大规模基于登记的数据集,我们发现甲状腺功能亢进个体患痴呆症的风险增加。与 TSH 正常的个体相比,TSH 每降低 6 个月,痴呆症的风险就会增加 16%。我们的数据支持对甲状腺功能亢进症患者进行早期诊断和干预。